公开(公告)号：US12091404B2

公开(公告)日：2024-09-17

申请号：US17690889

申请日：2022-03-09

申请人： Gilead Sciences, Inc.

发明人： Gediminas J. Brizgys ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Michael L. Mitchell ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang ,  Sheila M. Zipfel

IPC分类号： A61K31/4545 ,  A61K31/4439 ,  A61K45/06 ,  A61P1/16 ,  C07D211/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC分类号： C07D409/14 ,  A61K31/4545 ,  A61K45/06 ,  A61P1/16 ,  C07D405/14 ,  C07D417/14 ,  C07D211/14

摘要： The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US20240166602A1

公开(公告)日：2024-05-23

申请号：US18540293

申请日：2023-12-14

申请人： SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCIENCES

发明人： Bo LIU ,  Qingqiang YAO ,  Haijiao CHEN ,  Xinmei YANG ,  Ying ZHI ,  Ying LI ,  Haiyang WANG ,  Zhengguo CUI ,  Xiaoxiang LIU ,  Guodong HU ,  Tiandi DING ,  Feipeng ZHANG

IPC分类号： C07D211/14 ,  A61P35/00 ,  C07C217/64 ,  C07D207/06 ,  C07D211/82

CPC分类号： C07D211/14 ,  A61P35/00 ,  C07C217/64 ,  C07D207/06 ,  C07D211/82

摘要： The invention relates to the field of medicinal chemistry, in particular to a substituted diaryl compound shown as a formula (I), a preparation method of the substituted diaryl compound, a medicinal preparation containing the substituted diaryl compound and medical application of the substituted diaryl compound. Pharmacological test results show that the substituted diaryl compound disclosed by the invention has a good inhibition effect on cells of human lung cancer (A549), human ovarian cancer (SKOV3), human melanoma (A375) and human colon cancer (LOVO). The formula (I) is shown in the specification:

公开(公告)号：US20240116895A1

公开(公告)日：2024-04-11

申请号：US18135898

申请日：2023-04-18

申请人： Nocion Therapeutics, Inc.

发明人： Bridget McCarthy Cole ,  James Lamond Ellis

IPC分类号： C07D401/12 ,  C07D207/06 ,  C07D211/14 ,  C07D211/60 ,  C07D213/56 ,  C07D223/04 ,  C07D231/12

CPC分类号： C07D401/12 ,  C07D207/06 ,  C07D211/14 ,  C07D211/60 ,  C07D213/56 ,  C07D223/04 ,  C07D231/12 ,  A61K45/06

摘要： The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:




The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

公开(公告)号：US11952351B2

公开(公告)日：2024-04-09

申请号：US18059765

申请日：2022-11-29

申请人： KABUSHIKI KAISHA TOSHIBA

发明人： Mitsuko Ishihara ,  Eiichi Akahoshi ,  Katsuyuki Naito ,  Emi Nozaki ,  Saeko Saruwatari

IPC分类号： C07D243/08 ,  A61K9/127 ,  C07C229/30 ,  C07D211/14 ,  C07D233/02 ,  C07D241/04 ,  A61K31/7088

CPC分类号： C07D243/08 ,  A61K9/1271 ,  C07C229/30 ,  C07D211/14 ,  C07D233/02 ,  C07D241/04 ,  A61K31/7088

摘要： The present embodiment provides a compound represented by the formula (1):

Q-CHR2  (1)

(Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

公开(公告)号：US11945779B2

公开(公告)日：2024-04-02

申请号：US17052865

申请日：2019-05-02

申请人： VSpharmtech

发明人： Byoung-Mog Kwon ,  Dong Cho Han ,  Yae Jin Yoon ,  Yu Jin Lee ,  Jiyoun Choi ,  Sangku Lee

IPC分类号： A61K31/445 ,  A23L33/10 ,  A61K45/06 ,  C07D211/14

CPC分类号： C07D211/14 ,  A23L33/10 ,  A61K45/06

摘要： The present invention relates to a pharmaceutical composition for preventing or treating cancer metastasis, a health functional food, and a method for preventing or treating cancer metastasis using the same, containing a novel compound for inhibiting migration and invasion of cancer cells or a pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US11857550B2

公开(公告)日：2024-01-02

申请号：US16953201

申请日：2020-11-19

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Beibei Chen ,  Rama K. Mallampalli

IPC分类号： A61K31/506 ,  A61K31/137 ,  C07D239/26 ,  C07D403/12 ,  A61P3/10 ,  A61P11/06 ,  A61P19/00 ,  A61P25/00 ,  A61P35/00 ,  C07D231/12 ,  C07D233/61 ,  A61K31/341 ,  A61K31/381 ,  A61K31/402 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/5375 ,  C07D213/36 ,  C07C211/01 ,  C07C211/53 ,  C07C229/38 ,  C07D207/06 ,  C07D211/14 ,  C07D213/06 ,  C07D213/38 ,  C07D265/30 ,  C07D277/28 ,  A61K31/4178 ,  A61K31/435 ,  A61K31/444 ,  C07D233/64 ,  C07D401/12 ,  C07D295/135

CPC分类号： A61K31/506 ,  A61K31/137 ,  A61K31/341 ,  A61K31/381 ,  A61K31/402 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/435 ,  A61K31/444 ,  A61K31/4418 ,  A61K31/5375 ,  A61P3/10 ,  A61P11/06 ,  A61P19/00 ,  A61P25/00 ,  A61P35/00 ,  C07C211/01 ,  C07C211/53 ,  C07C229/38 ,  C07D207/06 ,  C07D211/14 ,  C07D213/06 ,  C07D213/36 ,  C07D213/38 ,  C07D231/12 ,  C07D233/61 ,  C07D233/64 ,  C07D239/26 ,  C07D265/30 ,  C07D277/28 ,  C07D295/135 ,  C07D401/12 ,  C07D403/12 ,  Y02A50/30

摘要： A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:






wherein X is a divalent linking moiety; and
R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

公开(公告)号：US20230174484A1

公开(公告)日：2023-06-08

申请号：US17997533

申请日：2021-04-30

申请人： Oregon Health & Science University

发明人： Sanjiv KAUL ,  Nabil ALKAYED ,  Shanthi NAGARAJAN ,  Agostino CIANCIULLI ,  Fabrizio MICHELI ,  Teresa SEMERARO ,  Iuni Margaret Laura TRIST

IPC分类号： C07D209/54 ,  C07D207/06 ,  C07D267/10 ,  C07D491/107 ,  C07D211/38 ,  C07D231/12 ,  C07D207/327 ,  C07D295/192 ,  C07D213/56 ,  C07D209/52 ,  C07D211/14 ,  C07D217/04 ,  C07D223/04 ,  C07D261/08 ,  C07D263/32 ,  C07D213/36 ,  C07D495/04 ,  C07D217/06 ,  C07D487/04 ,  C07D213/40 ,  C07D295/155 ,  C07D213/74 ,  C07D401/04 ,  C07D417/10 ,  C07D401/10 ,  C07D403/10 ,  C07D409/14 ,  C07D403/04 ,  C07D409/04 ,  C07D241/04 ,  C07D413/06 ,  C07D249/14 ,  C07D241/26 ,  C07D213/81 ,  C07D249/12 ,  C07D249/08 ,  C07D401/12 ,  C07F5/02 ,  C07D413/10 ,  C07D401/14 ,  C07D265/30 ,  C07D279/12 ,  C07D491/08 ,  C07D221/22 ,  C07D265/34 ,  A61P9/12 ,  A61P9/10

CPC分类号： C07D209/54 ,  C07D207/06 ,  C07D267/10 ,  C07D491/107 ,  C07D211/38 ,  C07D231/12 ,  C07D207/327 ,  C07D295/192 ,  C07D213/56 ,  C07D209/52 ,  C07D211/14 ,  C07D217/04 ,  C07D223/04 ,  C07D261/08 ,  C07D263/32 ,  C07D213/36 ,  C07D495/04 ,  C07D217/06 ,  C07D487/04 ,  C07D213/40 ,  C07D295/155 ,  C07D213/74 ,  C07D401/04 ,  C07D417/10 ,  C07D401/10 ,  C07D403/10 ,  C07D409/14 ,  C07D403/04 ,  C07D409/04 ,  C07D241/04 ,  C07D413/06 ,  C07D249/14 ,  C07D241/26 ,  C07D213/81 ,  C07D249/12 ,  C07D249/08 ,  C07D401/12 ,  C07F5/025 ,  C07D413/10 ,  C07D401/14 ,  C07D265/30 ,  C07D279/12 ,  C07D491/08 ,  C07D221/22 ,  C07D265/34 ,  A61P9/12 ,  A61P9/10

摘要： Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

公开(公告)号：US20230159446A1

公开(公告)日：2023-05-25

申请号：US18088447

申请日：2022-12-23

申请人： NANJING IMMUNOPHAGE BIOTECH CO., LTD.

发明人： Guohuang FAN ,  Hongyu YANG ,  Kin Chiu FONG ,  Jianfei WANG

IPC分类号： C07C311/46 ,  C07D211/12 ,  C07D211/14 ,  C07D215/36 ,  C07D241/44 ,  C07D239/93 ,  C07D209/48 ,  C07D239/42 ,  C07D235/08 ,  C07D401/12 ,  C07D231/56

CPC分类号： C07C311/46 ,  C07D211/12 ,  C07D211/14 ,  C07D215/36 ,  C07D241/44 ,  C07D239/93 ,  C07D209/48 ,  C07D239/42 ,  C07D235/08 ,  C07D401/12 ,  C07D231/56

摘要： The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

公开(公告)号：US20220371988A1

公开(公告)日：2022-11-24

申请号：US17754341

申请日：2020-09-29

申请人： NANJING DELOVA BIOTECH CO. LTD.

发明人： Qingsong WANG ,  Limin ZOU ,  Qu WU

IPC分类号： C07C233/09 ,  C07C233/20 ,  C07D211/58 ,  C07D207/06 ,  C07D211/14 ,  A61P25/04

摘要： A compound is represented by formula I. A stereoisomer, tautomer, solvate, polymorph of the compound or a pharmaceutically acceptable salt of the compound, a pharmaceutical composition containing the compound, a preparation method of the compound, and the medical use of the compound are provided.

公开(公告)号：US20210315895A1

公开(公告)日：2021-10-14

申请号：US16953201

申请日：2020-11-19

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Beibei Chen ,  Rama K. Mallampalli

IPC分类号： A61K31/506 ,  C07D231/12 ,  C07D233/61 ,  A61K31/137 ,  A61K31/341 ,  A61K31/381 ,  A61K31/402 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4418 ,  A61K31/5375 ,  C07D239/26 ,  C07D213/36 ,  A61P19/00 ,  A61P25/00 ,  A61P35/00 ,  A61P11/06 ,  A61P3/10 ,  C07C211/01 ,  C07C211/53 ,  C07C229/38 ,  C07D207/06 ,  C07D211/14 ,  C07D213/06 ,  C07D213/38 ,  C07D265/30 ,  C07D277/28 ,  A61K31/4178 ,  A61K31/435 ,  A61K31/444 ,  C07D233/64

摘要： A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.